Tag: finance

Gradiant Wins New Water Contracts for Major US Semiconductor Fabs in New York, Virginia, Idaho, and Utah

by jezzabellemente, posted in Uncategorized

Table

Gradiant today announced $300 million in new contracts from semiconductor manufacturing customers since the start of 2026.

$300 million in new ultrapure water, wastewater, and zero liquid discharge contracts mark continued commercial momentum in the chips layer of the AI economy

BOSTON, Sept 17 (Bernama-BUSINESS WIRE) — Gradiant, the water layer of the AI economy, today announced $300 million in new contracts from semiconductor manufacturing customers since the start of 2026, reflecting strong commercial momentum in a sector where water security is becoming a critical enabler of scale and speed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915041166/en/

Among the wins, Gradiant secured new contracts with several leading global semiconductor manufacturers across five fabrication sites in New York, Virginia, Idaho, and Utah. The projects include ultrapure water (UPW), high-recovery wastewater treatment, local scrubber reclaim, and zero liquid discharge (ZLD) systems designed to reduce freshwater demand, increase water reuse, and maximize production in increasingly water-constrained environments.

Rather than serving a single point in the water cycle, Gradiant will deliver its full semiconductor portfolio across these sites — from ultrapure water production to high-recovery wastewater treatment, scrubber reclaim, treatment of complex streams such as hydrofluoric-acid wastewater, and zero liquid discharge. Several of the awards are repeat contracts from existing customers, including the second phase of a high-recovery wastewater facility at one of the world’s largest semiconductor fabs and a scrubber reclaim design, already proven for the same customer in Singapore, Taiwan, and the U.S., that recovers more than 80 percent of feed volume.

“Water has become one of the defining constraints on how quickly the world can build the chips powering AI data centers, including high-bandwidth memory,” said Prakash Govindan, CEO of Gradiant. “That’s why leading semiconductor manufacturers keep choosing Gradiant: we own the full water cycle, from ultrapure water to the most complex wastewater streams, as one accountable partner. Water will not be the reason a fab falls behind.”

“These wins are exactly the kind of momentum we need to reach our target of a $1 billion U.S. order book next year,” said Nish Vora, Managing Director, Americas at Gradiant. “Each of these contracts reinforces Gradiant’s position as the water layer for semiconductors, eliminating water as a constraint for the companies building the chips the AI economy runs on.”

From ultrapure water and advanced wastewater treatment to high-recovery water reuse and ZLD systems, Gradiant’s semiconductor solutions are designed to help manufacturers increase capacity while reducing water consumption and environmental impact. As investment in AI infrastructure continues to accelerate, water management is becoming a critical enabler of how fast the next generation of semiconductor fabs can scale.

About Gradiant

Gradiant is the Water Layer of the AI Economy. Founded at MIT and headquartered in Boston, Gradiant builds the water and wastewater infrastructure behind AI’s build-out, from chips and data centers to the energy and industries that depend on them. As AI demand accelerates, water is becoming the resource that determines what can be built. Gradiant’s technologies reduce what industry withdraws, reclaim what it would waste, and renew clean water to nature, with more than 3,000 treatment plants built across 92 countries. Learn more at gradiant.com.

View source version on businesswire.com:
https://www.businesswire.com/news/home/20260915041166/en/

Contact

Corporate Contact
Felix Wang
Gradiant, Global Head of Marketing
fwang@gradiant.com

Source : Gradiant

Accertify’s Q2 Global Air Travel Fraud Report Finds Fraud Pressure Intensifying Across Middle East and Africa

by jezzabellemente, posted in Uncategorized

Analysis of nearly 133 million airline booking transactions finds bookings departing from Cairo carried the world’s highest fraud rate this quarter, while departure cities across the United States and Australia posted among the lowest fraud rates

ITASCA, Ill., July 16 (Bernama-BUSINESS WIRE) — Accertify, a leading fraud decisioning provider whose Predictive Yes Platform helps merchants say yes to more good customers, more revenue, and more growth, today announced the release of its Global Air Travel Fraud Report: Q2 2026, a quarterly analysis examining how fraud pressure varies across global airline markets based on departure city at time of booking.

Based on analysis of 132.9 million airline booking transactions processed between April and June 2026, the report evaluates prevented fraud rates across 537 departure cities that each processed at least 10,000 transactions during the quarter, providing airlines with a data-driven view of where Accertify’s Predictive Yes platform intervened most frequently at booking.

The Q2 findings reveal that fraud pressure continues to vary significantly by market, with the most notable shift occurring across the Middle East and Africa. The region’s average prevented fraud rate more than doubled quarter over quarter, from 0.95% to 2.03% — the highest of any region analyzed, against a global average of 0.29% — while bookings departing from Cairo, Accra, Tunis, and Casablanca posted the four highest fraud rates worldwide (Source: Accertify client data, Q2 2026). Meanwhile, departure cities across the United States and Australia continued to register some of the world’s lowest booking-stage fraud rates, reflecting the more mature fraud-prevention practices commonly found in those markets.

Key findings from the Accertify Q2 2026 Global Air Travel Fraud Report include:

  • Middle East and Africa recorded the highest average fraud rate of any region. The region’s average prevented fraud rate reached 2.03%, up from 0.95% in Q1 and well above the global average of 0.29%, with bookings departing from Cairo, Accra, Tunis, and Casablanca recording the four highest fraud rates worldwide.
  • Cairo reached the highest fraud rate in the world this quarter. The fraud rate on bookings departing from Cairo rose from 1.43% in Q1 to 6.57% in Q2 — moving it from 15th to the highest globally in a single quarter.
  • The United States and Australia reflected some of the world’s lowest fraud rates. Both remained well below the global average of 0.29%, with bookings departing from U.S. cities averaging 0.07% and bookings departing from Australia and Pacific cities averaging 0.08%.
  • East Asia posted the largest proportional improvement of any region. Its average prevented fraud rate nearly halved year over year, falling 43% from 0.20% to 0.11% — a steeper percentage decline than any other region, though Latin America + the Caribbean’s rate fell by more in absolute terms (0.91% to 0.69%).
  • Quarter-over-quarter rankings provide new insight into changing fraud patterns. For the first time, the report tracks how individual departure cities move within the global rankings from one quarter to the next, providing airlines with additional context into where fraud pressure is accelerating or easing over time.

The report underscores that fraud pressure is highly localized, often varying significantly between departure cities within the same region. By examining prevented fraud at the point of booking, airlines can better benchmark their own performance, identify emerging areas of elevated risk, and adapt fraud prevention strategies as booking patterns evolve.

Note on methodology: Fraud rate figures reflect prevented fraud – bookings denied for a fraud reason before travel occurred – denoted by departure city, the point of booking. Regional and global averages are calculated as the mean of each qualifying departure city’s individual fraud rate.

The Global Air Travel Fraud Report: Q2 2026 is hosted on Accertify’s website at https://www.accertify.com/q2-2026-global-air-travel-fraud-report/.

About Accertify

Accertify enables commerce by doing one thing extraordinarily well: pinpointing fraud. The company’s Predictive Yes Platform helps businesses say yes to more – more good customers, more revenue, and more growth – without getting burned. It’s a precise, confident, data-backed yes, made possible by joining signals across the entire customer lifecycle through unmatched data volume, layered AI-powered models, and a consortium approach that protects clients from bad actors spotted anywhere in the network while unlocking business with good actors verified anywhere in the network. With more than 10 billion transactions and over $1 trillion in commerce processed in 2025 alone, Accertify delivers the intelligence and precision that fraud and payments teams need to say yes confidently and enable growth. That’s the More Yes difference. Learn more at accertify.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260715427770/en/

Contact

Media Contact
Tylor Tourville
T2 PR
tylor@t2pr.agency

Source : Accertify

SINGAPORE’S TOP 100 BRANDS RISE 7 PCT TO US$84.1 BLN VALUE IN 2026

by jezzabellemente, posted in Uncategorized

KUALA LUMPUR, April 28 (Bernama) — Singapore’s top 100 brands rose seven per cent year-on-year to a combined value of US$84.1 billion in 2026, driven by growth across the banking, engineering, food and real estate sectors, according to the Brand Finance Singapore 100 2026 report. (US$1 = RM3.95)

DBS Bank retained its position as Singapore’s most valuable brand for the 14th consecutive year, with brand value rising eight per cent to US$18.6 billion, supported by regional expansion and diversification efforts.

Marina Bay Sands ranked second in brand value at US$8 billion, rising 35 per cent, supported by strong revenue performance and ongoing upgrade investments that enhanced its premium positioning in the tourism sector, while OCBC Bank ranked third at US$6.8 billion, reflecting steady performance in wealth management and regional expansion initiatives.

The report highlighted strong performance across sectors, with engineering benefiting from aerospace and defence demand, food and agriculture supported by commodity trends, and real estate remaining stable on steady transaction activity, according to a statement.

Meanwhile, Changi Airport was named Singapore’s strongest brand, with a Brand Strength Index score of 91.2 out of 100 and an AAA+ rating, driven by record passenger traffic, expanded connectivity and continued service investment.

TeleChoice International was the fastest-growing brand in the ranking, with brand value surging 288 per cent to US$52.7 million, driven by strong demand in semiconductor-related segments and product expansion.

Millennium Hotels and Resorts was the top hotel brand, ranking 27th overall, supported by digital transformation initiatives, loyalty programme growth and expansion of its global property portfolio.

Separately, Singapore Airlines led sustainability perceptions among Singaporean respondents, particularly for its decarbonisation strategy, including its net zero emissions target by 2050 and investment in sustainable aviation fuel.

Other brands showing strong sustainability perceptions included Ascott and Banyan Tree for environmental sustainability, CapitaLand, Singapore Land and FairPrice in social sustainability, and DBS in governance, reflecting strong domestic recognition across environmental, social, and governance (ESG) pillars.

— BERNAMA

GLOBAL WEALTH MIGRATION DRIVEN BY RISING PRIVATE HEALTHCARE COSTS – HENLEY & PARTNERS

by jezzabellemente, posted in Uncategorized

KUALA LUMPUR, Dec 9 (Bernama) — A sharp acceleration in global wealth migration in 2025 is colliding with rapidly diverging private healthcare costs worldwide, making the availability and price of reliable private care a key factor for high-net-worth families deciding where to live, invest, or secure residence and citizenship.

New data released by Henley & Partners confirms record demand for cross-border planning and highlights healthcare cost exposure as a critical “hidden variable” shaping long-term destination choices for globally mobile families.

The firm in a statement said it has received applications from 92 nationalities this year and supported demand across more than 50 residence and citizenship programmes and has assisted applicants from 136 nationalities over the past five years.

Comparing the first three quarters of 2024 with the same period in 2025, Henley & Partners reported a 43 per cent increase in applications, underscoring intensifying cross-border mobility among affluent households.

To support destination planning, the firm is referencing the newly published SIP Health Cost Index (HCI) 2025—a benchmark of the true cost of private healthcare across 50 key countries, based on International Private Medical Insurance (IPMI) premiums.

While Henley & Partners focuses on residence and citizenship advisory, the Index provides a complementary view into how private healthcare costs can materially affect a destination’s long-term affordability and suitability, especially for families with children, ageing parents, or elective cross-border medical needs.

The Index identifies familiar high-cost markets, with the United States ranking as the world’s most expensive private healthcare market, with an average annual IPMI-based cost of US$17,969 per person, followed by Hong Kong and Singapore. (US$1 = RM4.11)

However, unexpected shifts are emerging beyond traditional hubs. Several markets in emerging Asia—including China, Thailand, and Taiwan—have now entered the global top 12 for private-care costs, driven by strong demand for premium hospitals and rising inpatient expenses.

Europe shows one of the widest spreads, with the United Kingdom (UK), Greece, and Spain among its most expensive markets, partly due to Insurance Premium Tax in the UK and Greece. In the Middle East, the United Arab Emirates ranks 10th globally, reflecting expanding high-end healthcare infrastructure and medical-tourism ambitions.

As global wealth migration continues to rise, Henley & Partners said private healthcare cost exposure is becoming a first-order consideration in residence and citizenship planning. The SIP Health Cost Index provides a practical comparison tool to help families anticipate long-term healthcare budgets and avoid hidden high-cost risks when choosing a home, second residence, or multi-base lifestyle.

— BERNAMA

Datavault AI Inc. Announces a $10M Worldwide Exclusive License Agreement with Scilex Holding Company for Tokenization and Monetization of Real-World Assets (RWA) in Genomic, DNA Data, Diagnostics, Therapeutics, Genetic, and Drug Information

by jezzabellemente, posted in Uncategorized

PHILADELPHIA, Nov 5 (Bernama-GLOBE NEWSWIRE) — via IBN — Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), a leader in AI-driven blockchain solutions focusing on data monetization, asset tokenization, and secure digital marketplaces, today announced that it has granted a worldwide exclusive license, with the right to sublicense, to Scilex Holding Company (Nasdaq: SCLX), for Datavault AI’s proprietary AI-driven technology. This license is tailored for use within the biotech and biopharma industry, enabling Scilex to create and operate a Biotech Exchange platform. By leveraging Datavault AI’s advanced data platforms, Scilex can facilitate secure tokenization, trading, and monetization of biotech assets, including genomic and DNA data, diagnostic and therapeutic products, genetic information, and drug data. This agreement represents a major advancement in commercializing biotech innovations and builds directly on Datavault AI’s established expertise in high-performance computing and data-driven solutions.

Datavault AI believes this technology has the potential to extend into a Pharmaceutical Exchange platform, which could transform the pharmaceutical industry by enabling efficient, secure asset management and monetization.

Datavault AI estimates an opportunity to tokenize approximately $2.0 trillion in pharmaceutical drug sales and diagnostic sales.1 The Company also sees tokenization on such exchange platforms as an alternative for companies to secure non-dilutive funding for developing and commercializing diagnostic and therapeutic products.

This licensing agreement highlights Datavault AI’s robust intellectual property portfolio, including the key pending patent for “Platform and Method for Tokenizing DNA Data” (U.S. Patent Application No. 17/941,623), which establishes a secure framework for tokenizing and exchanging sensitive genetic information. The technology is bolstered by a comprehensive suite of issued and pending patents that power the Biotech Exchange, such as:

  • Issued: “Platform for Management of User Data” (U.S. Patent Nos. 11,593,515; 11,960,622; 12,100,025) and continuations, supporting secure data handling and monetization.
  • Issued: “Portfolio Driven Targeted Advertising Network, System, and Method” (U.S. Patent No. 11,315,150), facilitating data-driven targeting within exchange ecosystems.
  • Pending: “System and Method for Tokenized Minting, Authentication, and Utilization of Assets” (U.S. Patent Application No. 17/842,139), enabling biotech asset tokenization.
  • Pending: “Platform and Method for Tokenization of Corporate Data” (U.S. Patent Application No. 17/941,550), adaptable to biotech datasets.
  • Pending: “System and Method for Tokenized Licensing of Content” (U.S. Patent Application No. 17/842,328), for biotech IP licensing.
  • Pending: “System and Method for Tokenized Affiliate Marketing” (U.S. Patent Application No. 17/842,265), to foster biotech partnerships.
  • Pending: “System and Method for Funding a Virtual Location” (U.S. Patent Application No. 17/842,220), applicable to virtual biotech marketplaces.
  • Pending: “System and Method for Tokenized Event Management” (U.S. Patent Application No. 19/248,284), for biotech events and collaborations.
  • Pending: “System and Method for Registering Claims of Ownership Rights” (U.S. Patent Application No. 18/412,128), ensuring verifiable ownership in data trades.

These innovations collectively form the backbone of a secure, efficient Biotech Exchange, enabling tokenization, valuation, and trading of biotech data assets while upholding compliance and privacy.

Building on Datavault AI’s prior collaborations with Brookhaven National Laboratory, as announced in our June 17, 2025, press release, where we deployed AI-driven supercomputing for biofuel research to enhance fatty acid metabolism efficiency in Brassica napus (canola) using high-performance computational modeling, this license extends our proven AI and data monetization technologies into broader biotech applications. This follows our Sept. 16, 2024, announcement highlighting the Bioenergy Digital Twins Platform at the New York State Digital Summit, emphasizing real-time data synchronization and machine learning integration for bioenergy advancements.

Under the terms of the agreement, Datavault AI will receive a nonrefundable upfront license fee in four equal installments of $2.5 million each, payable by Scilex on or before December 31, 2025, March 31, 2026, June 30, 2026, and Sept. 30, 2026. Additionally, Datavault AI is eligible for sales milestone payments of up to an aggregate of $2.55 billion upon Scilex achieving certain sales milestones.

Terms of License

Under the terms of the agreement, Datavault AI will receive a non-refundable upfront license fee in four equal installments of $2.5 million each, payable by Scilex on or before December 31, 2025, March 31, 2026, June 30, 2026, and September 30, 2026. Additionally, Datavault AI is eligible for sales milestone payments of up to an aggregate of $2.55 billion upon Scilex achieving certain sales milestones.

For more information on Datavault AI, visit www.dvlt.ai.

About Datavault AI Inc.

Datavault AI™ (Nasdaq: DVLT) is leading the way in AI-driven data experiences, valuation, and monetization of assets. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division features WiSA®, ADIO®, and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization, and multi-channel interference cancellation. The Data Science Division leverages high-performance computing to provide solutions for experiential data perception, valuation, and secure monetization. Datavault AI’s cloud-based platform serves multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy, and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image, and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation, and advertising monitoring. The Company is headquartered in Philadelphia, Pennsylvania.

About Scilex Holding Company

Scilex is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA™” or “SP-102”), which is owned by Semnur (a majority-owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.

Scilex is headquartered in Palo Alto, California. For more information, visit www.scilexholding.com.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, the Company’s license agreement with Scilex, the potential opportunity to tokenize approximately $2.0 trillion in pharmaceutical drug sales and diagnostic sales, Datavault AI’s ability to support Scilex in leveraging its platforms for secure tokenization, trading, and monetization of biotech assets, the potential creation of a Pharmaceutical Exchange platform, expectations as to the opportunity to tokenize pharmaceutical drug sales and diagnostic sales, including the size of such opportunity, future opportunities for Datavault AI, its business strategies, long-term objectives, and commercialization plans, the current and prospective technologies, planned developments and potential approvals, as well as the potential for market acceptance and related market opportunities, and other statements that are not historical facts. These statements are based on management’s current expectations and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Datavault AI. These statements are subject to a number of risks and uncertainties regarding Datavault AI’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political, and business conditions; the ability of Datavault AI to achieve the benefits of the license agreement and other transactions contemplated with Scilex, including future financial and operating results; risks related to the outcome of any legal proceedings that may be instituted against the parties regarding the transactions contemplated with Scilex, including the license agreement; the risk that the transactions contemplated with Scilex disrupt current plans and operations; the ability of Datavault AI to develop and successfully market technologies; the ability of Datavault AI to grow and manage growth profitably and retain its key employees; the risk that the potential technologies that Datavault AI develops may not progress or receive required approvals within expected timelines or at all; risks relating to uncertainty regarding regulatory pathways; the risk that Datavault AI has overestimated the size of the target market, willingness to adopt new technologies, or partnerships; risks that prior results may not be replicated; regulatory and intellectual property risks; the risk of failure to realize the anticipated benefits of the transactions contemplated with Scilex; the risk that Datavault AI will not benefit from a Pharmaceutical Exchange platform; and other risks and uncertainties indicated from time to time in Datavault AI’s filings with the SEC. There may be additional risks that Datavault AI presently does not know or that Datavault AI currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Datavault AI’s expectations, plans, or forecasts of future events and views as of the date of this communication. Datavault AI anticipates that subsequent events and developments will cause such assessments to change. However, while Datavault AI may elect to update these forward-looking statements at some point in the future, Datavault AI specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Datavault AI’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements. 

Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

Media Inquiries:
marketing@dvlt.ai
Website: www.dvlt.ai

1References
Sources for Pharmaceutical Drug Sales Data

The data for global pharmaceutical drug sales was primarily drawn from IQVIA Institute reports on global medicine spending, excluding COVID-19 vaccines and therapeutics for consistency. Here is the list of key sources referenced:

Sources for Diagnostic Sales Data

The data for global in vitro diagnostics (IVD) market sales was compiled from market research reports, with forecasts based on observed CAGRs (around 6.9% from 2020-2024). IQVIA provides qualitative insights, but quantitative figures were cross-referenced from other industry analyses for accuracy. Here is the list of key sources referenced:

SOURCE: Datavault AI Inc. 

DISCLAIMER: BERNAMA MREM are not accountable for any causes of website defacement, misuse, or illegal activities connected to cryptocurrency, blockchain, tokenisation, or bitcoin. This material should not be considered as guidance or an opinion, as it does not constitute financial or investment advice. Use this information at your own risk; we are not liable for any losses or damages caused by the republication of this article.